US Map / Georgia
State GA

Clinical Trials in Georgia

Recruiting clinical trials with at least one study location in Georgia. Data updated daily from ClinicalTrials.gov.

Total Trials
298
Recruiting Now
298
← Back to US Map
Top Conditions in Georgia
Prostate Cancer (5)Endometrial Cancer (5)Malignant Solid Neoplasm (5)Multiple Myeloma (5)Breast Cancer (4)Ovarian Cancer (4)Lung Non-Small Cell Carcinoma (3)Non-Hodgkin Lymphoma (3)Overweight (3)Chronic Lymphocytic Leukemia (3)Alzheimer Disease (3)Small-cell Lung Cancer (3)
NCT05734066 Phase 1, Phase 2
Recruiting
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants Wit...
Condition
Refractory Ewing Sarcoma
Enrollment
60 pts
Location
United States, Canada
Sponsor
Jazz Pharmaceuticals
View Trial →
NCT01627301 N/A
Recruiting
Sympathetic Overactivity in Post-traumatic Stress Disorder
Condition
Post-traumatic Stress Disorder
Enrollment
120 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT05855200 Phase 3
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage ...
Condition
Colonic Neoplasms
Enrollment
892 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
View Trial →
NCT06683092 N/A
Recruiting
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Condition
Cystic Fibrosis
Enrollment
200 pts
Location
United States
Sponsor
Boston Children's Hospital
View Trial →
NCT07144254 Phase 1
Recruiting
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Condition
Osteosarcoma Recurrent
Enrollment
24 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT05905328 Phase 1, Phase 2
Recruiting
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Recei...
Condition
Cytokine Release Syndrome
Enrollment
54 pts
Location
United States
Sponsor
CytoAgents, Inc.
View Trial →
NCT06629428 EARLY_Phase 1
Recruiting
Effects of Ublituximab on Motor Functions in Multiple Sclerosis
Condition
Multiple Sclerosis (MS) - Relapsing-remitting
Enrollment
25 pts
Location
United States
Sponsor
Georgia State University
View Trial →
NCT07280065 Phase 3
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
Condition
PTSD - Post Traumatic Stress Disorder
Enrollment
1,900 pts
Location
United States, Australia
Sponsor
Senseye, Inc.
View Trial →
NCT05985161 Phase 2
Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Condition
Wilms Tumor
Enrollment
45 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance
View Trial →
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or ...
Condition
Colorectal Neoplasms
Enrollment
1,000 pts
Location
United States, Belgium, Brazil
Sponsor
Janssen Research & Development
View Trial →
NCT05283720 Phase 2
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneou...
Condition
Non-Hodgkin Lymphoma
Enrollment
496 pts
Location
United States, China, Czechia
Sponsor
Genmab
View Trial →
NCT04683653 Phase 1, Phase 2
Recruiting
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Condition
Endometrial Cancer
Enrollment
100 pts
Location
United States
Sponsor
University of Chicago
View Trial →
NCT02325674 N/A
Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
Condition
Generalised Lipodystrophy
Enrollment
100 pts
Location
United States, France, Germany
Sponsor
Amryt Pharma
View Trial →
NCT06932588 N/A
Recruiting
Biomarker Role in Assessing Imaging Needs for Mild Cranial Trauma
Condition
Brain Injuries
Enrollment
350 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT03547973 Phase 2
Recruiting
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Canno...
Condition
Metastatic Urothelial Cancer
Enrollment
827 pts
Location
United States, France, Germany
Sponsor
Gilead Sciences
View Trial →
NCT07096674 Phase 2
Recruiting
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopa...
Condition
Narcolepsy Type 1
Enrollment
90 pts
Location
United States
Sponsor
Centessa Pharmaceuticals (UK)
View Trial →
NCT04989803 Phase 1, Phase 2
Recruiting
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-...
Condition
Relapsed and/or Refractory B-cell Lymphoma
Enrollment
247 pts
Location
United States, Australia, Germany
Sponsor
Kite, A Gilead Company
View Trial →
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Condition
Chronic Lymphocytic Leukemia
Enrollment
700 pts
Location
United States, Argentina, Australia
Sponsor
Janssen Research & Development
View Trial →
NCT07441694 Phase 1
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Condition
Myeloproliferative Neoplasms
Enrollment
218 pts
Location
United States, Australia, Belgium
Sponsor
Incyte Corporation
View Trial →
NCT06252753 N/A
Recruiting
Observational Study Protocol: LIVER-R
Condition
Hepatobiliary Cancers
Enrollment
4,490 pts
Location
United States, Australia, Austria
Sponsor
AstraZeneca
View Trial →
NCT04293562 Phase 3
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilterit...
Condition
Acute Myeloid Leukemia
Enrollment
1,186 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group
View Trial →
NCT05213676 Phase 4
Recruiting
De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia
Condition
Congenital Diaphragmatic Hernia
Enrollment
600 pts
Location
United States
Sponsor
The University of Texas Health
View Trial →
NCT07223268 N/A
Recruiting
Comprehensive Assistance and Resources for Effective Diabetic Foot Navigation
Condition
Diabetic Foot Ulcer
Enrollment
270 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT07288320 Phase 2
Recruiting
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults...
Condition
Bipolar I Disorder
Enrollment
150 pts
Location
United States
Sponsor
Neurocrine Biosciences
View Trial →
NCT04237623 Phase 2
Recruiting
GM-CSF With Post-Transplant Cyclophosphamide
Condition
Transplant-Related Hematologic Malignancy
Enrollment
38 pts
Location
United States
Sponsor
Northside Hospital, Inc.
View Trial →
Page 5 of 12 — 298 trials total
← Prev Next →